Janux Therapeutics, Inc. JANX
Set alert
At close · Nov 2
After hours · Nov 2, 4:05 PM ET
- YTD
- +26.52%
- 1 year
- -39.18%
- Open
- 17.50
- Prev close
- 17.47
- Mkt cap
- 1.07B
- Vol
- 410.34K
- Avg vol
- 827.01K
- EPS
- -1.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.40
- High
- 17.82
- Forward P/E
- -6.65
- Beta
- 2.39
- Short ratio
- 5.72
- Inst. own
- 101.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 17.60
- 200-d avg
- 15.33
- 1y target
- 33.81
6M chart
Events in this range
- May 7, 2026Earnings: -0.39; estimate -0.5202; surprise 25.03%
- May 8, 2026Rating: Guggenheim · Buy → Buy
- May 8, 2026Rating: Wedbush · Outperform → Outperform
- May 8, 2026Rating: Piper Sandler · Overweight → Overweight
- Aug 6, 2026Earnings: -0.35; estimate -0.2513; surprise -39.28%
- Aug 7, 2026Rating: Guggenheim · Buy → Buy
- Aug 24, 2026Rating: Wolfe Research · Peer Perform → Outperform
Signals (33)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| RSI: Overbought | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| RSI: Overbought | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| SMA: Bearish | May 26, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| SMA: Bullish | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 8, 2026 | 5 months ago |
Key statistics
- Market cap
- 1.07B
- Enterprise value
- 118.14M
- Trailing P/E
- 0.00
- Forward P/E
- -6.65
- PEG ratio
- 0.00
- Price / sales
- 44.48
- Price / book
- 1.15
- EPS (TTM)
- -1.64
- Beta
- 2.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 24.00M
- Revenue growth
- 0.00%
- Free cash flow
- -16.39M
- Total cash
- 970.91M
- Total debt
- 20.99M
- Return on equity
- -10.70%
- Shares outstanding
- 61.14M
- Short % of float
- 11.15%
- 50-day average
- 17.60
- 200-day average
- 15.33
Analyst view
Consensus: strong buy
- Target (low)
- 14.00
- Target (mean)
- 33.81
- Target (high)
- 60.00
- Strong buy2
- Buy14
- Hold1
- Sell0
- Strong sell1
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.48843.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.47372 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.2513 | -0.35 | -0.10 | -39.28% |
| May 7, 2026 | Mar 31, 2026 | -0.5202 | -0.39 | +0.13 | +25.03% |
| Feb 26, 2026 | Dec 31, 2025 | -0.65 | -0.51 | +0.14 | +21.54% |
| Nov 6, 2025 | Sep 30, 2025 | -0.60 | -0.39 | +0.21 | +35.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.48 | -0.55 | -0.07 | -14.58% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | Wolfe Research | up | Peer Perform | Outperform |
| Aug 7, 2026 | Guggenheim | main | Buy | Buy |
| May 8, 2026 | Piper Sandler | main | Overweight | Overweight |
| May 8, 2026 | Wedbush | main | Outperform | Outperform |
| May 8, 2026 | Guggenheim | main | Buy | Buy |
| Apr 28, 2026 | Jones Trading | main | Buy | Buy |
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- januxrx.com
News
- Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head Survey
- Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)
- 4 Prostate Cancer Drug Stocks to Watch During Awareness Month
- Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer
- Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
- This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
- Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
- Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More
- JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
- Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55
Your note
Sign in to keep a note on JANX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAMPBELL DAVID ALAN | Officer and Director | Stock Gift | Jul 30, 2026 | 264,742 |
| CAPPS VICKIE LYNN | Director | Stock Award(Grant) | Jun 10, 2026 | 79,598 |
| DIRAIMONDO THOMAS PH.D. | Officer | Sale | Jan 1, 2026 | 155,825 |
| DOYLE JANEEN NOEL | Officer | Sale | Jun 1, 2026 | 75,941 |
| GO WILLIAM M.D., PH.D. | Officer | Stock Award(Grant) | Feb 1, 2026 | 44,000 |
| GUJRATHI SHEILA | Director | Stock Award(Grant) | Jun 10, 2025 | 118,889 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 18.30% | 11,189,693 | 195.37M | Jun 29, 2026 |
| Blackrock Inc. | 10.03% | 6,134,667 | 107.11M | Jun 29, 2026 |
| Prosight Management, Lp | 6.22% | 3,804,481 | 66.43M | Jun 29, 2026 |
| State Street Corporation | 4.92% | 3,004,899 | 52.47M | Jun 29, 2026 |
| FMR, LLC | 3.95% | 2,412,825 | 42.13M | Jun 29, 2026 |
| Federated Hermes, Inc. | 3.85% | 2,352,927 | 41.08M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes MDT Series-Federated Hermes MDT Small Cap Core Fund | 2.25% | 1,374,115 | 23.99M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.07% | 1,263,837 | 22.07M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.01% | 1,227,373 | 21.43M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.86% | 1,134,393 | 19.81M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.90% | 552,368 | 9.64M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.77% | 471,460 | 8.23M | Jul 30, 2026 |